Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 20/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 9/20 | 0.83 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bitopertin SCHEMBL29363611 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL29985866 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL3772885 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL562490 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| Bitopertin SCHEMBL561853 | 0.91 | SLC6A9 (1.00) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5042013 | 0.86 | SLC6A9 (0.82) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL12172477 | 0.84 | SLC6A9 (0.88) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL5038316 | 0.84 | SLC6A9 (0.70) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL4424343 | 0.84 | SLC6A9 (0.87) | SLC6A9KCNH2SLC6A5 | |
| SCHEMBL23815759 | 0.84 | SLC6A9 (0.71) | SLC6A9KCNH2SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9877963-B2 | GlyT1 inhibitors for use in the treatment of hematological disorders | HOFFMANN-LA ROCHE INC. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20170042888-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170042888-A1 | GLYT1 INHIBITORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | SLC40A1, GFPT1, HBG1 | SLC6A9 121/4885KCNH2 3010/4885SLC6A5 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.